

Benjamin S Braun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5919515/publications.pdf>

Version: 2024-02-01

25
papers

1,715
citations

566801

15
h-index

713013

21
g-index

25
all docs

25
docs citations

25
times ranked

2929
citing authors

#	ARTICLE	IF	CITATIONS
1	The <i>EBF1-PDGFRB</i> T681I mutation is highly resistant to imatinib and dasatinib <i>in vitro</i> and detectable in clinical samples prior to treatment. <i>Haematologica</i> , 2021, 106, 2242-2245.	1.7	3
2	<i>Nf1</i> and <i>Sh2b3</i> mutations cooperate <i>in vivo</i> in a mouse model of juvenile myelomonocytic leukemia. <i>Blood Advances</i> , 2021, 5, 3587-3591.	2.5	1
3	Fusion driven JMML: a novel <i>CCDC88C</i> - <i>FLT3</i> fusion responsive to sorafenib identified by RNA sequencing. <i>Leukemia</i> , 2020, 34, 662-666.	3.3	27
4	<i>Kras</i> P34R and <i>Kras</i> T58I mutations induce distinct RASopathy phenotypes in mice. <i>JCI Insight</i> , 2020, 5, .	2.3	10
5	<i>Bcl-2</i> Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia. <i>Cancer Research</i> , 2019, 79, 2339-2351.	0.4	55
6	Tissue-Specific Oncogenic Activity of <i>KRASA146T</i> . <i>Cancer Discovery</i> , 2019, 9, 738-755.	7.7	127
7	Paroxysmal cold hemoglobinuria successfully treated with complement inhibition. <i>Blood Advances</i> , 2019, 3, 3575-3578.	2.5	19
8	A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. <i>Cancer Research</i> , 2017, 77, 5706-5711.	0.4	22
9	Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia. <i>Nature Communications</i> , 2017, 8, 2127.	5.8	75
10	Traxtile: Interactive editing of cell tracks in time-lapse images. <i>BioTechniques</i> , 2015, 59, 82-6.	0.8	0
11	Subclonal mutations in <i>SETBP1</i> confer a poor prognosis in juvenile myelomonocytic leukemia. <i>Blood</i> , 2015, 125, 516-524.	0.6	69
12	Targeting oncogenic Ras signaling in hematologic malignancies. <i>Blood</i> , 2012, 120, 3397-3406.	0.6	171
13	The PI3K Inhibitor GDC-0941 Attenuates Disease in a <i>Kras</i> G12D Mouse Model of CMML and JMML. <i>Blood</i> , 2012, 120, 2862-2862.	0.6	1
14	Hematopoiesis and leukemogenesis in mice expressing oncogenic <i>Nras</i> G12D from the endogenous locus. <i>Blood</i> , 2011, 117, 2022-2032.	0.6	132
15	Germline <i>CBL</i> mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. <i>Nature Genetics</i> , 2010, 42, 794-800.	9.4	308
16	Oncogenic <i>Kras</i> Initiates Leukemia in Hematopoietic Stem Cells. <i>PLoS Biology</i> , 2009, 7, e1000059.	2.6	89
17	The SPS Affair: A Complex Tale of Illicit Proliferation. <i>Cancer Cell</i> , 2009, 16, 87-88.	7.7	0
18	Pediatric malignancies: update on sarcomas and leukemia development in children. <i>Current Opinion in Genetics and Development</i> , 2009, 19, 92-96.	1.5	1

#	ARTICLE	IF	CITATIONS
19	Targeting Ras in Myeloid Leukemias. <i>Clinical Cancer Research</i> , 2008, 14, 2249-2252.	3.2	57
20	K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells. <i>Blood</i> , 2007, 109, 3945-3952.	0.6	103
21	Intracellular Signals as Molecular Biomarkers for Therapeutic Responses in Kras Mutant Myeloid Cells.. <i>Blood</i> , 2007, 110, 2196-2196.	0.6	0
22	Leukemogenic K-RasG12D Induces Cell Cycle Entry and Clonal Dominance in Hematopoietic Stem Cells.. <i>Blood</i> , 2007, 110, 778-778.	0.6	0
23	Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 597-602.	3.3	279
24	The sum is greater than the FGFR1 partner. <i>Cancer Cell</i> , 2004, 5, 203-204.	7.7	4
25	Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. <i>Blood</i> , 2004, 103, 4243-4250.	0.6	162